Petosemtamab Plus Pembrolizumab Shows Strong Efficacy in Head and Neck Cancer

Merus N.V. announced positive interim data from a Phase 2 trial of petosemtamab in combination with pembrolizumab for first-line treatment of PD-L1+ r...